Mechanism of p300 Specific Histone Acetyltransferase Inhibition by Small Molecules

被引:88
作者
Arif, M. [1 ]
Pradhan, Suman Kalyan [2 ]
Thanuia, G. R. [1 ]
Vedamurthy, B. M. [1 ]
Agrawal, Shipra [3 ]
Dasgupta, Dipak [2 ]
Kundu, Tapas K. [1 ]
机构
[1] Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Mol Biol & Genet Unit, Transcript & Dis Lab, Bangalore 560064, Karnataka, India
[2] Saha Inst Nucl Phys, IAF, Div Biophys, Kolkata 700064, India
[3] ITPB, Inst Bioinformat & Appl Biotechnol, Bangalore 560066, Karnataka, India
关键词
TRANSCRIPTION; ACETYLATION; DOMAIN; COACTIVATOR; ACTIVATION; CBP/P300; PCAF; GCN5; CBP; HAT;
D O I
10.1021/jm800657z
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Dysfunction of histone acetyltransferases (HATs) leads to several diseases including cancer, diabetes, and asthma. Therefore, small molecule inhibitors and activators of HATs are being considered as new generation therapeutics. Here, we report the molecular mechanisms of p300 HAT inhibition by specific and nonspecific HAT inhibitors: garcinol, isogarcinol, and 1 (LTK 14). The p300 specific HAT inhibitor 1 behaves as a noncompetitive inhibitor for both acetyl-CoA and histone, unlike nonspecific HAT inhibitors garcinol and isogarcinol. The isothermal calorimetric data suggest that there is a high affinity enthalpy driven single binding site for 1 on p300HAT domain in contrast to two binding sites for garcinol and isogarcinol. Furthermore, the precise nature of molecular interactions was determined by using fluorescence, docking, and mutational studies. On the basis of these observations, we have proposed the mechanisms of specific versus nonspecific HAT inhibition by these small molecule compounds, which may be useful to design therapeutically favorable HAT inhibitors.
引用
收藏
页码:267 / 277
页数:11
相关论文
共 38 条
[31]   Selective inhibition of CBP/p300 HAT [J].
Sarli, Vasiliki ;
Giannis, Athanassios .
CHEMISTRY & BIOLOGY, 2007, 14 (06) :605-606
[32]   The p300/CBP family: Integrating signals with transcription factors and chromatin [J].
Shikama, N ;
Lyon, J ;
LaThangue, NB .
TRENDS IN CELL BIOLOGY, 1997, 7 (06) :230-236
[33]  
Swaminathan V, 2007, Subcell Biochem, V41, P397
[34]   Transcriptional coactivator protein p300 - Kinetic characterization of its histone acetyltransferase activity [J].
Thompson, PR ;
Kurooka, H ;
Nakatani, Y ;
Cole, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) :33721-33729
[35]   Regulation of the p300 HAT domain via a novel activation loop [J].
Thompson, PR ;
Wang, DX ;
Wang, L ;
Fulco, M ;
Pediconi, N ;
Zhang, DZ ;
An, WJ ;
Ge, QY ;
Roeder, RG ;
Wong, JM ;
Levrero, M ;
Sartorelli, V ;
Cotter, RJ ;
Cole, PA .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2004, 11 (04) :308-315
[36]   Chromatin modifications (acetylation/deacetylation/methylation) as new targets for HIV therapy [J].
Varier, Radhika A. ;
Kundu, Tapas K. .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (16) :1975-1993
[37]   Chromatin remodeling: why it is important in cancer [J].
Wolffe, AP .
ONCOGENE, 2001, 20 (24) :2988-2990
[38]   Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein [J].
Zhou, XY ;
Shibusawa, N ;
Naik, K ;
Porras, D ;
Temple, K ;
Ou, HS ;
Kaihara, K ;
Roe, MW ;
Brady, MJ ;
Wondisford, FE .
NATURE MEDICINE, 2004, 10 (06) :633-637